Potential evidence for epigenetic biomarkers of metabolic syndrome in human whole blood in Latinos

Metabolic syndrome (MetS) is highly prevalent worldwide. In the United States, estimates show that more than 30% of the adult population has MetS. MetS consists of multiple phenotypes, including obesity, dyslipidemia, and impaired glucose tolerance. Therefore, identifying the molecular mechanisms to...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Keane Urashima, Anastasia Miramontes, Luis A. Garcia, Dawn K. Coletta
Formato: article
Lenguaje:EN
Publicado: Public Library of Science (PLoS) 2021
Materias:
R
Q
Acceso en línea:https://doaj.org/article/40e90f1650ba4eab8e7655749178ecf2
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:40e90f1650ba4eab8e7655749178ecf2
record_format dspace
spelling oai:doaj.org-article:40e90f1650ba4eab8e7655749178ecf22021-11-04T06:49:31ZPotential evidence for epigenetic biomarkers of metabolic syndrome in human whole blood in Latinos1932-6203https://doaj.org/article/40e90f1650ba4eab8e7655749178ecf22021-01-01T00:00:00Zhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8555810/?tool=EBIhttps://doaj.org/toc/1932-6203Metabolic syndrome (MetS) is highly prevalent worldwide. In the United States, estimates show that more than 30% of the adult population has MetS. MetS consists of multiple phenotypes, including obesity, dyslipidemia, and impaired glucose tolerance. Therefore, identifying the molecular mechanisms to explain this complex disease is critical for diagnosing and treating MetS. We previously showed 70 increased genes and 20 decreased genes in whole blood in MetS participants. The present study aimed to identify blood-based DNA methylation biomarkers in non-MetS versus MetS participants. The present study analyzed whole blood DNA samples from 184 adult participants of Latino descent from the Arizona Insulin Resistance (AIR) registry. We used the National Cholesterol Education Program Adult Treatment Panel III (NCEP: ATP III) criteria to identify non-MetS (n = 110) and MetS (n = 74) participants. We performed whole blood methylation analysis on select genes: ATP Synthase, H+ Transporting mitochondrial F1 Complex, Epsilon Subunit (ATP5E), Cytochrome C Oxidase Subunit VIc (COX6C), and Ribosomal Protein L9 (RPL9). The pyrosequencing analysis was a targeted approach focusing on the promoter region of each gene that specifically captured CpG methylation sites. In MetS participants, we showed decreased methylation in two CpG sites in COX6C and three CpG sites in RPL9, all p < 0.05 using the Mann-Whitney U test. There were no ATP5E CpG sites differently methylated in the MetS participants. Furthermore, while adjusting for age, gender, and smoking status, logistic regression analysis reaffirmed the associations between MetS and mean methylation within COX6C and RPL9 (both p < 0.05). In addition, Spearman’s correlation revealed a significant inverse relationship between the previously published gene expression data and methylation data for RPL9 (p < 0.05). In summary, these results highlight potential blood DNA methylation biomarkers for the MetS phenotype. However, future validation studies are warranted to strengthen our findings.Keane UrashimaAnastasia MiramontesLuis A. GarciaDawn K. ColettaPublic Library of Science (PLoS)articleMedicineRScienceQENPLoS ONE, Vol 16, Iss 10 (2021)
institution DOAJ
collection DOAJ
language EN
topic Medicine
R
Science
Q
spellingShingle Medicine
R
Science
Q
Keane Urashima
Anastasia Miramontes
Luis A. Garcia
Dawn K. Coletta
Potential evidence for epigenetic biomarkers of metabolic syndrome in human whole blood in Latinos
description Metabolic syndrome (MetS) is highly prevalent worldwide. In the United States, estimates show that more than 30% of the adult population has MetS. MetS consists of multiple phenotypes, including obesity, dyslipidemia, and impaired glucose tolerance. Therefore, identifying the molecular mechanisms to explain this complex disease is critical for diagnosing and treating MetS. We previously showed 70 increased genes and 20 decreased genes in whole blood in MetS participants. The present study aimed to identify blood-based DNA methylation biomarkers in non-MetS versus MetS participants. The present study analyzed whole blood DNA samples from 184 adult participants of Latino descent from the Arizona Insulin Resistance (AIR) registry. We used the National Cholesterol Education Program Adult Treatment Panel III (NCEP: ATP III) criteria to identify non-MetS (n = 110) and MetS (n = 74) participants. We performed whole blood methylation analysis on select genes: ATP Synthase, H+ Transporting mitochondrial F1 Complex, Epsilon Subunit (ATP5E), Cytochrome C Oxidase Subunit VIc (COX6C), and Ribosomal Protein L9 (RPL9). The pyrosequencing analysis was a targeted approach focusing on the promoter region of each gene that specifically captured CpG methylation sites. In MetS participants, we showed decreased methylation in two CpG sites in COX6C and three CpG sites in RPL9, all p < 0.05 using the Mann-Whitney U test. There were no ATP5E CpG sites differently methylated in the MetS participants. Furthermore, while adjusting for age, gender, and smoking status, logistic regression analysis reaffirmed the associations between MetS and mean methylation within COX6C and RPL9 (both p < 0.05). In addition, Spearman’s correlation revealed a significant inverse relationship between the previously published gene expression data and methylation data for RPL9 (p < 0.05). In summary, these results highlight potential blood DNA methylation biomarkers for the MetS phenotype. However, future validation studies are warranted to strengthen our findings.
format article
author Keane Urashima
Anastasia Miramontes
Luis A. Garcia
Dawn K. Coletta
author_facet Keane Urashima
Anastasia Miramontes
Luis A. Garcia
Dawn K. Coletta
author_sort Keane Urashima
title Potential evidence for epigenetic biomarkers of metabolic syndrome in human whole blood in Latinos
title_short Potential evidence for epigenetic biomarkers of metabolic syndrome in human whole blood in Latinos
title_full Potential evidence for epigenetic biomarkers of metabolic syndrome in human whole blood in Latinos
title_fullStr Potential evidence for epigenetic biomarkers of metabolic syndrome in human whole blood in Latinos
title_full_unstemmed Potential evidence for epigenetic biomarkers of metabolic syndrome in human whole blood in Latinos
title_sort potential evidence for epigenetic biomarkers of metabolic syndrome in human whole blood in latinos
publisher Public Library of Science (PLoS)
publishDate 2021
url https://doaj.org/article/40e90f1650ba4eab8e7655749178ecf2
work_keys_str_mv AT keaneurashima potentialevidenceforepigeneticbiomarkersofmetabolicsyndromeinhumanwholebloodinlatinos
AT anastasiamiramontes potentialevidenceforepigeneticbiomarkersofmetabolicsyndromeinhumanwholebloodinlatinos
AT luisagarcia potentialevidenceforepigeneticbiomarkersofmetabolicsyndromeinhumanwholebloodinlatinos
AT dawnkcoletta potentialevidenceforepigeneticbiomarkersofmetabolicsyndromeinhumanwholebloodinlatinos
_version_ 1718445081839534080